

1 **Effectiveness of inactive COVID-19 vaccines against severe illness in B.1.617.2**  
2 **(Delta) variant-infected patients in Jiangsu, China**

3

4 **Zhiliang Hu<sup>1,2 †</sup>, Bilin Tao<sup>2†</sup>, Zhongqi Li<sup>2†</sup>, Yan Song<sup>1</sup>, Changhua Yi<sup>1</sup>, Junwei Li<sup>1</sup>,**  
5 **Meng Zhu<sup>2</sup>, Yongxiang Yi<sup>1\*</sup>, Peng Huang<sup>2\*</sup>, Jianming Wang<sup>2\*</sup>**

6 <sup>1</sup>Nanjing Public Health Medical Center, the Second Hospital of Nanjing, Nanjing  
7 University of Chinese Medicine, Nanjing, 210003 China.

8 <sup>2</sup>Department of Epidemiology, Center for Global Health, School of Public Health,  
9 Nanjing Medical University, Nanjing, 211166 China

10

11 †These authors have contributed equally to this work

12

13 **\*Corresponding authors:**

14 **Yongxiang Yi.** Nanjing Public Health Medical Center, the Second Hospital of Nanjing,  
15 Nanjing University of Chinese Medicine, 1-1 Zhongfu Rd., Nanjing, 210003, China.

16 Telephone: 025-83626203. Email: [ian0126@126.com](mailto:ian0126@126.com)

17 **Peng Huang.** Nanjing Medical University, 101 Longmian Ave., Nanjing, 211166,  
18 China. Telephone: 025-86868291. Email: [huangpeng@njmu.edu.cn](mailto:huangpeng@njmu.edu.cn)

19 **Jianming Wang.** Nanjing Medical University, 101 Longmian Ave., Nanjing, 211166,  
20 China. Telephone: 025-86868414. Email: [jmwang@njmu.edu.cn](mailto:jmwang@njmu.edu.cn)

21 **Abstract**

22 The SARS-CoV-2 B.1.617.2 (Delta) variant has caused a new surge in the number of  
23 COVID-19 cases. The effectiveness of vaccines against this variant is not fully  
24 understood. Using data from a recent large-scale outbreak of COVID-19 in China, we  
25 conducted a real-world study to explore the effect of inactivated vaccine immunization  
26 on the course of disease in patients infected with Delta variants. We recruited 476  
27 confirmed cases over the age of 18, of which 42 were severe. After adjusting for age,  
28 gender, and comorbidities, patients who received two doses of inactivated vaccine  
29 (fully vaccinated) had an 88% reduced risk in progressing to the severe stage (adjusted  
30 OR: 0.12, 95% CI: 0.02- 0.45). However, this protective effect was not observed in  
31 patients who only received only one dose of the vaccine(adjusted OR: 1.11, 95% CI:  
32 0.51- 2.36). The full immunization offered 100% protection from a severe illness  
33 among women. The effect of the vaccine was potentially affected by underlying medical  
34 conditions (OR: 0.26, 95% CI: 0.03-1.23). This is the largest real-world study  
35 confirming the effectiveness of inactive COVID-19 vaccines against severe illness in  
36 Delta variant-infected patients in Jiangsu, China.

37

38 **Keywords:** COVID-19; SARS-CoV-2; Delta variant; vaccine; effectiveness; severe  
39 illness

## 40 **Introduction**

41 According to estimation by World Health Organization (WHO), as of August 24, 2021,  
42 the global cumulative number of confirmed coronavirus disease 2019 (COVID-19)  
43 cases has risen to over 210 million, and more than 4.4 million people have died from  
44 it[1]. There is no doubt that vaccination is a vital measure to contain the global COVID-  
45 19 pandemic. Different COVID-19 vaccines, including inactivated, adenovirus vector,  
46 and mRNA vaccines, have been authorized or in the laboratory development and  
47 clinical utility evaluation stage[2, 3, 4, 5]. As of August 23, 2021, over 4.6 billion doses  
48 of the COVID-19 vaccines have been administered globally[1]. These vaccines can  
49 effectively induce immune responses against severe acute respiratory syndrome  
50 coronavirus 2 (SARS-CoV-2) infection[6, 7, 8]. Clinical trials outside China  
51 demonstrated that vaccine efficacy for preventing symptomatic COVID-19 ranged from  
52 65.9% to 83%, and severe illness or ICU admission ranged from 90% to 100%[9, 10,  
53 11]. In China, the masses are generally vaccinated with inactivated vaccines.  
54 Accumulated evidence suggests that inactivated COVID-19 vaccine could efficiently,  
55 although not wholly, protect from SARS-CoV-2 infection and, importantly, prevent  
56 severe illness progression. However, it is difficult to confirm in mainland China because  
57 there was no large-scale local outbreak after the first epidemic wave in 2020. Moreover,  
58 the protective effect of the inactivated vaccine on the pathogenesis of SARS-CoV-2  
59 mutant strains is not clear.

60

61 On July 20, 2021, nine domestic COVID-19 cases were identified through a regular  
62 screening in Nanjing Lukou international airport, China[12]. The epidemic gathered at  
63 the airport spread rapidly to the surrounding areas, leading to outbreaks in Nanjing,  
64 Yangzhou, and Zhangjiajie. Genome sequencing confirmed that the etiologic agent was

65 the SARS-CoV-2 B.1.617.2 (Delta) variant, which was first identified in Maharashtra,  
66 India, in late 2020 and now has spread globally[13]. Compared with the original type  
67 of SARS-CoV-2, the Delta variant has a significantly increased virulence and  
68 transmission ability[14, 15, 16]. Furthermore, the protective effect of vaccines against  
69 Delta variant infection is found to be weakened in many studies[17, 18, 19, 20, 21].

70

71 In the case of more than 200 million doses of COVID-19 vaccine have been  
72 administered in China, whether the widely used inactivated vaccine is still effective for  
73 Delta variants is a question worthy of discussion. Thus, we performed a real-world  
74 study using patients' clinical and epidemiological data in a designated hospital in  
75 Nanjing. They were all linked to the outbreak of COVID-19 in Nanjing Lukou  
76 international airport. Our study aimed to describe to what extent the inactivated vaccine  
77 could prevent COVID-19 from progressing to severe illness in patients infected with  
78 the SARS-CoV-2 Delta variant.

79

## 80 **Methods**

### 81 *Study design and population*

82 We recruited 476 confirmed COVID-19 cases treated in the isolation wards of Nanjing  
83 Public Health Medical Center from June to July. The inclusive criteria were patients: 1)  
84 aged over 18 years, 2) confirmed by SARS-CoV-2 nucleic acid PCR test, 3) linked to  
85 the recent outbreak of COVID-19 originated in Nanjing Lukou international airport, 4)  
86 infected with Delta variant. The Nanjing Public Health Medical Center is the only  
87 designated hospital that provides medical services for COVID-19 patients in Nanjing.  
88 Of the 476 patients recruited in this study, 189 lived in Nanjing, 273 lived in Yangzhou,  
89 12 lived in Huaian, and two lived in Suqian. We collected data of each patient, including

90 demographic characteristics, medical history, vaccine status, comorbidities, clinical  
91 features, laboratory tests, treatments, and outcomes. The onset date was defined as  
92 when symptoms first appeared, or asymptomatic patients were detected for the first  
93 time with SARS-CoV-2 nucleic acid positive. The diagnosis of severe illness was based  
94 on the “Guideline of COVID-19 Diagnosis and Treatment (trial version 8)” issued by  
95 the National Health Council of China. This study was approved by the ethics committee  
96 of Nanjing Public Health Medical Center. Written informed consent was waived by the  
97 Ethics Commission.

98

### 99 ***Vaccination status***

100 The information regarding the time of vaccination and the type of the vaccines were  
101 obtained from the electronic health information system. The time interval between the  
102 last dose of vaccination and the onset of disease was calculated. Because two weeks  
103 after the second dose were needed to develop protective immune responses against  
104 SARS-CoV-2 infection, an effective vaccine shot was considered only when the time  
105 interval between the second shot and disease onset was at least 14 days. We categorized  
106 patients into three groups: unvaccinated, partially vaccinated, and fully vaccinated  
107 according to the immunization history. Patients would also be considered unvaccinated  
108 if they had received one dose but the time interval between the first shot and illness  
109 onset was less than 14 days. Likewise, patients, who had received two vaccine shots,  
110 however, the time interval between the second shot and illness onset was less than 14  
111 days, would be considered partially vaccinated[22].

112

### 113 ***Outcomes***

114 The primary outcome of interest was the progression to severe illness in patients

115 infected with the Delta variant. As defined by the “Guideline of COVID-19 Diagnosis  
116 and Treatment (trial version 8)” in China, severe illness of COVID-19 for adult patients  
117 should meet one of the following criteria: 1) respiratory rate  $\geq 30$  breaths/min, 2) at  
118 rest, the oxygen saturation of fingers during air inhalation is  $\leq 93\%$ , 3) arterial partial  
119 pressure of oxygen ( $\text{PaO}_2$ ) / oxygen uptake concentration ( $\text{FiO}_2$ )  $\leq 300$  mmHg, 4)  
120 clinical symptoms were aggravated, and the pulmonary imaging showed that the lesion  
121 progressed more than 50% within 24-48 hours. Patients with critical COVID-19 were  
122 those who had developed respiratory failure requiring mechanical ventilation or had  
123 evidence of shock or other organ dysfunctions that needed transferring to the intensive  
124 care unit (ICU)[23]. The most severe condition of the patients during the hospitalization  
125 was recorded. In this study, we analyzed severe and critical cases together.

126

### 127 *Covariates*

128 Covariates that have been confirmed to or possibly have a role in disease progression  
129 were considered, including age, gender, comorbidities, vaccination status, baseline  
130 SARS-CoV-2 viral load, and therapies (corticosteroids, intravenous immunoglobulin,  
131 and aerosol interferon- $\alpha$ ). Age was categorized into two groups: 18-59 years and  $\geq 60$   
132 years. Clinical parameters such as blood lymphocyte counts, C-reactive protein (CRP) ,  
133 Interleukin-6 (IL-6), D-dimer, lactate dehydrogenase (LDH), and pulmonary  
134 involvement were more appropriate to an index of disease severity rather than the risk  
135 factors, thereby were not included in the multivariable regression analysis. All cases  
136 involved in this study were vaccinated with the inactivated vaccine.

137

### 138 *Statistical analysis*

139 Categorized variables were expressed as frequency, and continuous variables were  
140 described as the median (interquartile range, IQR). Comparison between groups was  
141 made using the Chi-Square test, Mann-Whitney U-test, or Fisher's exact test, as  
142 appropriate. Factors related to severe illness were analyzed by univariate and  
143 multivariate regression analysis, and the relationship was expressed with odds ratio (OR)  
144 and 95% confidence interval (95% CI). We also performed a subgroup analysis by  
145 stratifying age, gender, and underlying medical conditions. The significance level was  
146 set at 0.05. All analyses were performed using R software for Windows version 4.0.5  
147 (<https://www.r-project.org/>).

148

## 149 **Results**

### 150 *Demographics and clinical characteristics*

151 A total of 476 hospitalized patients were included in the analysis, of which 42 (8.82%)  
152 were severe cases. Over 60% of patients were female. The median age of patients with  
153 severe and non-severe illnesses was 69.50 (IQR: 59.00-75.00) years and 51.00 (IQR:  
154 40.00-66.00) years. Patients with severe illness tended to had more underlying medical  
155 conditions (50.00% vs. 30.02%), including hypertension (35.71% vs. 21.71%), diabetes  
156 (19.05% vs. 8.08%), heart disease (11.90% vs. 3.70%) and COPD (4.76% vs. 0.23%).  
157 No significant difference was observed between the two groups in gender and history  
158 of cancer, asthma, or autoimmune diseases. Time from disease onset to hospitalization  
159 was similar in patients with severe or non-severe illness, with a median time of 3 days.  
160 In patients without severe innless, there were 157 (36.18%) unvaccinated, 92 (21.20%)  
161 partially vaccinated, and 185 (42.63%) fully vaccinated. In contrast, in patients with  
162 severe illness, the proportion of unvaccinated, partially vaccinated, and fully vaccinated

163 was 64.29%, 0.95%, and 4.76%, respectively. (Table 1).

164

### 165 *Signs and symptoms*

166 Initial symptoms were fever, dry cough, sputum production, chest tightness or shortness  
167 of breath, nausea or vomiting, abdominal pain or diarrhea, loss of smell or taste,  
168 myalgia, stuffy or runny nose, headache or dizziness, fatigue, and pharyngeal  
169 discomfort. Patients with severe illness had a higher proportion of fever (61.90% vs.  
170 31.87%) and shortness of breath (19.05% vs. 3.46%) than those without severe illness.  
171 Besides, the patients with severe illness were commonly cough, sputum production,  
172 nausea or vomiting, abdominal pain or diarrhea, myalgia, headache, or dizziness, but  
173 the difference was not statistically significant (Table 1).

174

### 175 *Laboratory parameters, microbiological and serological data*

176 As shown in Table 1, patients who progressed to severe illness had relatively higher  
177 levels of baseline CRP, procalcitonin, IL-6, aspartate aminotransferase, alanine  
178 aminotransferase, urea nitrogen, creatinine, creatine kinase, myoglobin, troponin I,  
179 LDH, prothrombin time, and D-dimer. Baseline levels of the white blood cell count,  
180 lymphocyte count, neutrophil count, hemoglobin, total bilirubin, CK-MB, and  
181 fibrinogen degradation products were similar between the two groups. Patients without  
182 severe illness had a higher IgG and IgM antibody to SARS-CoV-2. There were no  
183 significant differences in viral load threshold cycle value (Ct) detecting ORF1ab and O  
184 gene.

185

### 186 *Estimate the efficacy of inactivated SARS-CoV-2 vaccine*

187 Severe illness occurred in 14.7% (27/184), 12.4% (13/105), and 1.1% (2/187) of the



188 unvaccinated, partially vaccinated) and fully vaccinated patients, respectively. As pre-  
189 defined in the methods, patients who had received one dose of vaccine and had acquired  
190 Delta variant infection within 14 days were deemed unvaccinated. This 14-days elapsed  
191 time was also applicable to the second dose vaccination. There was no significant  
192 difference in the proportion of severe illness between patients who did not receive any  
193 COVID-19 vaccine and patients having one dose within 14 days (15.6% vs. 12.2%,  $P$   
194 =0.75 ), or between patients who did not receive any COVID-19 vaccine and patients  
195 having the 2nd dose within 14 days (12.8% vs. 11.1 %,  $P=1$ ). Therefore, our estimation  
196 of the effectiveness of vaccines would not be significantly biased by the definition of  
197 vaccination status.

198

199 Compared with the unvaccinated group, those fully vaccinated ones had a significantly  
200 decreased risk of severe illness (OR: 0.06, 95% CI: 0.01-0.21,  $P<0.001$ ; risk reduction:  
201 94%, 95% CI: 79%-99%). The risk of severe illness was also decreased for the partially  
202 vaccinated person but not significant (OR: 0.822, 95% CI: 0.393-1.643).

203

204 After adjusting for the potential confounders, such as gender, age, and underlying  
205 medical conditions, the protective effect of full vaccination remained significant  
206 (adjusted OR: 0.12, 95% CI: 0.02- 0.45,  $P=0.006$ ; adjusted risk reduction: 88%, 95%CI:  
207 55%-98%). No significant effect was found for partial vaccination (adjusted OR: 1.11,  
208 95% CI: 0.51- 2.36,  $P=0.783$ ) (Table 2).

209

### 210 ***Subgroup analysis***

211 The risk of progressing to severe illness reached 0 in fully vaccinated persons without  
212 underlying medical conditions, age  $\geq 60$  years or female. Only 14 elderly patients were

213 fully vaccinated, so that the protection may be overestimated in this subgroup. The  
214 protective effect of severe illness remained significant for 18-59 years fully vaccinated  
215 persons (adjusted OR: 0.12, 95% CI: 0.02-0.61, P: 0.016; risk reduction: 88%, 95% CI:  
216 39%-98%) and male fully vaccinated persons (adjusted OR: 0.19, 95% CI: 0.03-0.86,  
217 P=0.049; risk reduction: 81%, 95% CI: 14%-97%). The effect of the vaccine was  
218 potentially affected by underlying medical conditions, resulting in reduced protective  
219 effect of full vaccination (OR: 0.26, 95% CI: 0.03-1.23). Partial vaccination had no  
220 significant protective effect on severe illness in all subgroups (P >0.05) (Table 2).

221

## 222 **Discussion**

223 Mutations of the SARS- CoV-2 have attracted significant public attention, with variants  
224 of concerns leading to increased transmissibility, impaired immune protection by the  
225 vaccine, more severe disease, or compromised diagnostic capacity[24]. The Delta  
226 variant, which was first identified in India, is more transmittable than other lineages of  
227 SARS-CoV-2 and now is becoming the major strain causing the COVID-19 pandemic  
228 [25, 26, 27]. Vaccine breakthrough caused by the Delta variant has been increasingly  
229 reported, even in the massively vaccinated regions [27, 28]. Therefore, the concern has  
230 been raised regarding whether herd immunity in China established extensively by  
231 inactive vaccines could protect against the Delta variant.

232

233 In late May, the first attack by this new virus occurred in Guangzhou, China, with about  
234 160 cases involved[29]. A real-world study on 74 patients and 292 negative controls  
235 calculated that the overall effect for two-dose vaccination was 59.0% against SARS-  
236 CoV-2 infection and 100% against severe illness[22]. Our present study, focusing on  
237 476 hospitalized patients, demonstrated that the risk of progression to severe illness had

238 substantially decreased in fully vaccinated patients. After adjusting for age, sex, and  
239 underlying medical conditions, the risk reduction remained significant, with an 88%  
240 risk reduction. This is the largest real-world study to confirm the effectiveness of  
241 inactivated vaccines in preventing severe illness caused by Delta variants in China.

242

243 It is well known that underlying comorbidities and old age are risk factors for severe  
244 illness in SARS-CoV-2 infected patients[30]. This is consistent with findings from our  
245 study. Severe illness did not occur in fully vaccinated patients without underlying  
246 medical conditions (100% protection). Both of the two fully vaccinated patients who  
247 developed severe illness had underlying diseases. Interestingly, 100% protection was  
248 also found in elderly patients that had been fully vaccinated. Since only 14 elderly  
249 patients were fully vaccinated, the protective effect of inactive vaccines might be  
250 overestimated in this study. Fully vaccinated women were 100% prevented from  
251 progressing to severe illness, while fully vaccinated men had only 81% reduced risk.  
252 Whether sex disparities exist in COVID-19 vaccine efficacy needs to be further  
253 explored.

254

255 Although an entire course of vaccination could efficiently protect the COVID-19  
256 patients from progressing to severe illness, the protective effect could not be identified  
257 in partially vaccinated ones. This may be due to a relatively high viral burden and a  
258 decreased immune protection in Delta variant-infected patients [19, 20, 29]. The  
259 baseline viral load in this study, as represented by Ct value of the real-time quantitative  
260 reverse transcription polymerase chain reaction (RT-PCR) was 20 (IQR: 16-25), which  
261 is much higher than that (median: 30; IQR: 25-34) in our previous data during the first  
262 outbreak of COVID-19 in 2020[31]. In the context of Delta variant infection, a

263 relatively higher immunity may be necessary, which generally would be achieved after  
264 a full vaccination[8].

265

266 There are some limitations to our study. First, we confirmed the protective effect of  
267 inactivated vaccines from progressing to severe illness, but we could not estimate the  
268 vaccine efficacy against Delta variant infection because all participants were confirmed  
269 COVID-19 cases. Second, since individuals who have been protected from infection  
270 would not develop a severe illness related to COVID-19, the effectiveness of inactive  
271 vaccines against severe illness in our study based on infected cases would be, to some  
272 extent, an underestimation of that based on the whole population.

273

274 In conclusion, we found a full course immunization with inactivated vaccines could  
275 effectively protect against severe illness caused by the Delta variant in China. The  
276 protective effect is affected by underlying medical conditions. Partial vaccination does  
277 not offer clinically meaningful protection against severe illness. Our study highlights  
278 the importance of continuing effort on a full course of vaccination.

279

#### 280 **Conflict of interest statement**

281 All authors have no conflict of interest to declare.

282

#### 283 **Acknowledgements**

284 We would like to thank all the heroic people for their active participation in ending this  
285 COVID-19 outbreak and for taking care of the patients.

286

#### 287 **Funding**

288 This study was supported by Key Research and Development Program of Department  
289 of Health of Jiangsu (ZDB2020036), and Project of Nanjing Infectious Disease Clinical  
290 Medical Center Construction (NA2021062071). The funders had no role in study  
291 design, data collection, and analysis, decision to publish, or preparation of the  
292 manuscript.

293

## 294 **References**

- 295 1. WHO. WHO Coronavirus (COVID-19) Dashboard 2021 [25th August 2021].  
296 Available from: <https://covid19.who.int/>
- 297 2. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the  
298 ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a  
299 phase 1/2, single-blind, randomised controlled trial. *Lancet* (London, England).  
300 2020 Aug 15;396(10249):467-478. doi: 10.1016/s0140-6736(20)31604-4.  
301 PubMed PMID: 32702298; PubMed Central PMCID: PMC7445431. eng.
- 302 3. Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-  
303 CoV-2 Vaccine in Chile. *New England Journal of Medicine*. 2021 Jul  
304 7;385(10):875-884. doi: 10.1056/NEJMoa2107715. PubMed PMID: 34233097;  
305 PubMed Central PMCID: PMC8279092. eng.
- 306 4. Kandeil A, Mostafa A, Hegazy RR, et al. Immunogenicity and Safety of an  
307 Inactivated SARS-CoV-2 Vaccine: Preclinical Studies. *Vaccines*. 2021 Mar  
308 3;9(3):214. doi: 10.3390/vaccines9030214. PubMed PMID: 33802467;  
309 PubMed Central PMCID: PMC7999656. eng.
- 310 5. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2  
311 mRNA Covid-19 Vaccine. *New England Journal of Medicine*. 2020 Dec  
312 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. PubMed PMID:  
313 33301246; PubMed Central PMCID: PMC7745181. eng.
- 314 6. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated  
315 SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-  
316 controlled, phase 1/2 trial. *The Lancet Infectious Diseases*. 2021 Jan;21(1):39-  
317 51. doi: 10.1016/S1473-3099(20)30831-8. PubMed PMID: 33069281; PubMed  
318 Central PMCID: PMC7561304. eng.
- 319 7. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an  
320 inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a  
321 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *The  
322 Lancet Infectious Diseases*. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-  
323 3099(20)30843-4. PubMed PMID: 33217362; PubMed Central PMCID:

- 324 PMCPMC7832443. eng.
- 325 8. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of  
326 vaccine-induced protection against COVID-19 in humans. *Nature Reviews*  
327 *Immunology*. 2021 2021/08/01;21(8):475-484. doi: 10.1038/s41577-021-  
328 00578-z.
- 329 9. Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines  
330 on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.  
331 *Jama*. 2021 Jul 6;326(1):35-45. doi: 10.1001/jama.2021.8565. PubMed PMID:  
332 34037666; PubMed Central PMCID: PMCPMC8156175 Y. Yang, Ms Y. Zhao,  
333 Ms H. Wang, and Mr Li reported receiving grants from the Ministry of Science  
334 and Technology of the People's Republic of China (2020YFC0842100) during  
335 the conduct of the study. Dr Yuntao Zhang, Ms Y Yang, Ms Xuqin Yang, Mr Lai,  
336 Ms Q. Wang, Mr T. Yang, Mr Liu, and Dr Xiaoming Yang are employees of the  
337 China National Biotec Group Company Limited; Mr Li, Mr Chen and Drs  
338 Huang and Duan are employees of the Wuhan Institute of Biological Products  
339 Co, Ltd; and Mr W. Wang, Mr Ma, Ms Y. Zhao, and Ms H. Wang are employees  
340 of the Beijing Institute of Biological Products Co, Ltd—all companies that  
341 developed the vaccine and sponsored the trial. Drs Jiang and G. Zhao are  
342 employees of the Beijing Key-Tech Statistical Consulting Co, Ltd, and received  
343 fees from the China National Biotec Group Company Limited to conduct the  
344 data analysis. Drs Al Kaabi, Abdalla, Hussein, Al Mazrouei, Al Karam, Hussain,  
345 and Khan and Mr Fasihuddin reported being an employee of Abu Dhabi Health  
346 Services Company. Drs Mahmoud and Zaher, Mr ElTantawy, Mr Xiao, and Mr  
347 Koshy reported being an employee of the G42 Healthcare. Ms H. Wang reported  
348 receiving grants from the Beijing Municipal Science & Technology  
349 Commission during the conduct of the study and having a patent for  
350 202010575098.9 pending, a patent for 202010537733.4 pending, a patent for  
351 202010537730.0 pending, a patent for 202110052921.2 pending, and a patent  
352 for 202110052933.5 pending. Drs Xiaoming Yang and Duan and Mr Li have a  
353 patent for 202010559132.3 pending. No other disclosures were reported. eng.
- 354 10. Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an  
355 inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of  
356 a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *The*  
357 *Lancet*. 2021 Jul 17;398(10296):213-222. doi: 10.1016/s0140-6736(21)01429-  
358 x. PubMed PMID: 34246358; PubMed Central PMCID: PMCPMC8266301.  
359 eng.
- 360 11. Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-  
361 CoV-2 Vaccine in Chile. *New England Journal of Medicine*. 2021. doi:  
362 10.1056/NEJMoa2107715.
- 363 12. Nanjing Municipal Health Commission. Brief on the condition of positive sars-  
364 cov-2 test from Lukou international airport.

- 365 [http://wjw.nanjing.gov.cn/njswshjhjshywyh/202107/t20210721\\_3080544.html](http://wjw.nanjing.gov.cn/njswshjhjshywyh/202107/t20210721_3080544.html).  
366 July 21, 2021.
- 367 13. Joint Prevention and Control Mechanism of the State Council. Brief on COVID-  
368 19 prevention and control. <http://www.gov.cn/xinwen/gwylflkjz161/wzslqt.htm>.  
369 July 31, 2021.
- 370 14. Liu Y, Rocklöv J. The reproductive number of the Delta variant of SARS-CoV-  
371 2 is far higher compared to the ancestral SARS-CoV-2 virus. *Journal of travel*  
372 *medicine*. 2021 Aug 9. doi: 10.1093/jtm/taab124. PubMed PMID: 34369565;  
373 eng.
- 374 15. Burki TK. Lifting of COVID-19 restrictions in the UK and the Delta variant.  
375 *The Lancet Respiratory Medicine*. 2021 Aug;9(8):e85. doi: 10.1016/S2213-  
376 2600(21)00328-3. PubMed PMID: 34265238; PubMed Central PMCID:  
377 PMC8275031. eng.
- 378 16. Li XN, Huang Y, Wang W, et al. Efficacy of inactivated SARS-CoV-2 vaccines  
379 against the Delta variant infection in Guangzhou: A test-negative case-control  
380 real-world study. *Emerging microbes & infections*. 2021 Aug 14:1-32. doi:  
381 10.1080/22221751.2021.1969291. PubMed PMID: 34396940; eng.
- 382 17. Sheikh A, McMenamin J, Taylor B, et al. SARS-CoV-2 Delta VOC in Scotland:  
383 demographics, risk of hospital admission, and vaccine effectiveness. *The Lancet*.  
384 2021 Jun 26;397(10293):2461-2462. doi: 10.1016/S0140-6736(21)01358-1.  
385 PubMed PMID: 34139198; PubMed Central PMCID: PMC8201647 AS  
386 and CR are members of the New and Emerging Respiratory Virus Threats  
387 Advisory Group (NERVTAG) risk stratification subgroup. JM is a member of  
388 NERVTAG. CR is a member of the Scientific Pandemic Influenza Group on  
389 Modelling. AS is a member of AstraZeneca's Thrombotic Thrombocytopenic  
390 Advisory Group. All roles are unremunerated. JM, BT, and CR are employed  
391 by Public Health Scotland. Acknowledgments are listed in the appendix.
- 392 18. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines  
393 against the B.1.617.2 (Delta) Variant. *New England Journal of Medicine*.  
394 2021;385(7):585-594. doi: 10.1056/NEJMoa2108891.
- 395 19. Nasreen S, Chung H, He S, et al. Effectiveness of COVID-19 vaccines against  
396 variants of concern in Ontario, Canada. *medRxiv*. 2021:2021.06.28.21259420.  
397 doi: 10.1101/2021.06.28.21259420.
- 398 20. Musser JM, Christensen PA, Olsen RJ, et al. Delta variants of SARS-CoV-2  
399 cause significantly increased vaccine breakthrough COVID-19 cases in  
400 Houston, Texas. *medRxiv*. 2021:2021.07.19.21260808. doi:  
401 10.1101/2021.07.19.21260808.
- 402 21. Chen L-L, Lu L, Choi CY-K, et al. Impact of Severe Acute Respiratory  
403 Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding  
404 Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by  
405 Coronavirus Disease 2019 (COVID-19) Infection or Vaccination. *Clinical*

- 406 Infectious Diseases. 2021. doi: 10.1093/cid/ciab656.
- 407 22. Li X-n, Huang Y, Wang W, et al. Efficacy of inactivated SARS-CoV-2 vaccines  
408 against the Delta variant infection in Guangzhou: A test-negative case-control  
409 real-world study. *Emerging microbes & infections*. 2021:1-32. doi:  
410 10.1080/22221751.2021.1969291.
- 411 23. Joint Prevention and Control Mechanism of the State Council. Chinese interim  
412 guidance of novel coronavirus pneumonia (version 8.0).  
413 [http://www.nhc.gov.cn/xcs/zhengcwj/202008/0a7bdf12bd4b46e5bd28ca7f9a7f](http://www.nhc.gov.cn/xcs/zhengcwj/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a/files/a449a3e2e2c94d9a856d5faea2ff0f94.pdf)  
414 [5e5a/files/a449a3e2e2c94d9a856d5faea2ff0f94.pdf](http://www.nhc.gov.cn/xcs/zhengcwj/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a/files/a449a3e2e2c94d9a856d5faea2ff0f94.pdf).
- 415 24. Khateeb J, Li Y, Zhang H. Emerging SARS-CoV-2 variants of concern and  
416 potential intervention approaches. *Critical Care*. 2021 2021/07/12;25(1):244.  
417 doi: 10.1186/s13054-021-03662-x.
- 418 25. Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility  
419 and global spread of SARS-CoV-2 variants of concern as at June 2021.  
420 *Eurosurveillance*. 2021;26(24):2100509. doi: [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2021.26.24.2100509)  
421 [7917.ES.2021.26.24.2100509](https://doi.org/10.2807/1560-7917.ES.2021.26.24.2100509).
- 422 26. Singh J, Rahman SA, Ehtesham NZ, et al. SARS-CoV-2 variants of concern are  
423 emerging in India. *Nature medicine*. 2021;27(7):1131-1133. doi:  
424 10.1038/s41591-021-01397-4.
- 425 27. Vaughan A. Delta to dominate world. *New Sci*. 2021;250(3341):9. doi:  
426 10.1016/S0262-4079(21)01121-0.
- 427 28. Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2  
428 Breakthrough Infections to Time-from-vaccine; Preliminary Study. *medRxiv*.  
429 2021:2021.07.29.21261317. doi: 10.1101/2021.07.29.21261317.
- 430 29. Li B, Deng A, Li K, et al. Viral infection and transmission in a large, well-traced  
431 outbreak caused by the SARS-CoV-2 Delta variant. *medRxiv*.  
432 2021:2021.07.07.21260122. doi: 10.1101/2021.07.07.21260122.
- 433 30. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and  
434 death. *BMJ*. 2020;368:m1198. doi: 10.1136/bmj.m1198.
- 435 31. Hu Z, Lv Y, Xu C, et al. Clinical Use of Short-Course and Low-Dose  
436 Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia  
437 Progression. *Frontiers in Public Health*. 2020 2020-July-03;8(355). doi:  
438 10.3389/fpubh.2020.00355.
- 439



**Table 1. Baseline characteristics and clinical features of 476 Delta variant-infected patients with or without severe illness**

	Non-severe illness n=434, n (%) or median (IQR)	Severe illness n=42, n (%) or median (IQR)	P
<b>Demographics and clinical characteristics</b>			
Gender			0.321
Female	267 (61.52)	22 (52.38)	
Male	167 (38.48)	20 (47.62)	
Age group, years	51.00 (40.00, 66.00)	69.50 (59.00-75.00)	<0.001
18-59	286 (65.90)	12 (28.57)	<0.001
≥60	148 (34.10)	30 (71.42)	
Having underlying medical conditions	130 (30.02)	21 (50.00)	0.013
Hypertension	94 (21.71)	15 (35.71)	0.062
Diabetes	35 (8.08)	8 (19.05)	0.037
Heart disease	16 (3.70)	5 (11.90)	0.038
Carcinoma history	9 (2.08)	2 (4.76)	0.253
COPD	1 (0.23)	2 (4.76)	0.022
Asthma	8 (1.85)	1 (2.38)	0.569
Autoimmune diseases	4 (0.93)	1 (2.38)	0.372
Vaccination Status			<0.001
Unvaccinated	157 (36.18)	27 (64.29)	
Partially vaccinated	92 (21.20)	13 (30.95)	
Fully vaccinated	185 (42.63)	2 (4.76)	
Time from illness onset to hospitalization (days)	3.00 (1.00, 5.00)	3.00 (2.00,5.00)	0.152
<b>Clinical features</b>			
Fever	138 (31.87)	26 (61.90)	<0.001
Cough	221 (51.04)	23 (54.76)	0.765
Sputum production	84 (19.35)	8 (19.05)	1.000
Shortness of breath	15 (3.46)	8 (19.05)	<0.001
Nausea or vomiting	9 (2.08)	2 (4.76)	0.253
Abdominal pain or diarrhea	25 (5.76)	3 (7.14)	0.728
Loss of smell or taste	18 (4.15)	1 (2.38)	1.000
Myalgia	11 (2.53)	3 (7.14)	0.117
Stuffy nose or runny nose	64 (14.75)	3 (7.14)	0.245
Headache or dizziness	30 (6.91)	5 (11.90)	0.382
Fatigue	91 (20.97)	8 (19.05)	0.925
Pharyngeal discomfort	97 (22.35)	6 (14.29)	0.310
<b>Laboratory findings</b>			
C-reactive protein , mg/L	4.96 (1.89, 13.99)	25.94 (11.22-36.50)	<0.001
>10	288 (66.36)	10 (23.81)	<0.001
Procalcitonin, ng/mL	0.04 (0.02, 0.06)	0.09 (0.06-0.14)	<0.001
<0.1	385 (89.33)	26 (61.90)	
0.1-	43 (9.98)	12 (28.57)	
0.25-	2 (0.46)	2 (4.76)	
0.5-	1 (0.23)	2 (4.76)	
Interleukin-6, pg/mL	10.25 (3.48, 20.52)	37.67 (22.00-72.61)	<0.001
>6.6	159 (36.89)	1 (2.38)	<0.001
White blood cell count, × 10 <sup>9</sup> /L	4.81 (3.88, 5.93)	4.67 (3.99,5.96)	0.779
<4	128 (29.49)	11 (26.19)	0.869
4	298 (68.66)	31 (73.81)	
10-	8 (1.84)	0 (0.00)	
Neutrophil count, × 10 <sup>9</sup> /L	3.04 (2.18, 3.93)	3.22 (2.37,4.17)	0.423

Lymphocyte count, × 10 <sup>9</sup> /L	1.16 (0.86, 1.56)	1.04 (0.88,1.27)	0.063
<0.8	78 (17.97)	8 (19.05)	1.000
Hemoglobin, g/L	131.00 (122.00, 145.00)	132.00 (123.25,138.00)	0.617
Platelet count, × 10 <sup>9</sup> /L	157.00 (123.25, 193.75)	117.50 (92.50,144.75)	<0.001
<100	54 (12.44)	14 (33.33)	0.001
Albumin, g/L	42.60 (40.30, 45.20)	40.10 (37.30,42.18)	<0.001
Total bilirubin, umol/L	9.80 (7.70, 12.40)	10.10 (8.33,13.05)	0.532
Aspartate aminotransferase, IU/L	17.05 (13.83, 23.28)	25.15 (19.72,37.70)	<0.001
>40	35 (8.06)	9 (21.43)	0.010
Alanine aminotransferase, U/L	17.85 (12.33, 28.25)	23.80 (14.10,32.05)	0.038
>40	57 (13.13)	7 (16.67)	0.686
Urea nitrogen, mmol/L	4.44 (3.64, 5.29)	5.10 (3.84,6.45)	0.012
Creatinine, μmol/L	60.25 (51.80, 74.80)	71.20 (59.50,81.68)	0.001
>104	11 (2.53)	3 (7.14)	0.117
eGFR, ml/min	111.38 (101.28, 121.21)	92.85 (83.95,107.70)	0.001
<90	31 (10.10)	7 (43.75)	<0.001
Creatine kinase, U/L	67.50 (47.00, 106.00)	133.00 (64.25,209.75)	<0.001
>174	47 (10.93)	15 (35.71)	<0.001
CK-MB, ng/ml	0.50 (0.30, 0.90)	0.60 (0.40,0.90)	0.183
>3.1	11 (2.94)	1 (2.38)	1.000
Myoglobin, ng/mL	33.40 (21.25, 58.10)	66.50 (38.10,107.20)	<0.001
>106	37 (9.97)	11 (26.83)	0.003
Troponin I, pg/ml	3.00 (0.72, 6.65)	10.10 (4.50,18.60)	<0.001
>15.6	29 (7.92)	14 (34.15)	<0.001
Lactate dehydrogenase, U/L	235.00 (204.00, 274.00)	312.50 (240.00,378.75)	<0.001
>245	188 (43.32)	31 (73.81)	<0.001
Prothrombin time, s	11.10 (10.80, 11.60)	11.50 (11.10,11.80)	0.003
D-dimer, μg/L	0.39 (0.25, 0.64)	0.46 (0.32,0.88)	0.018
>0.55	132 (30.41)	18 (42.86)	0.138
FDPs, ug/ml	2.70 (1.77, 5.33)	3.55 (2.70,5.35)	0.120
<b>Microbiological and serological data</b>			
Viral load (Ct value)			
ORF1ab gene	23.00 (19.00, 28.00)	23.00 (21.00,26.75)	0.633
N gene	20.00 (16.00, 25.00)	20.00 (16.25,23.00)	0.850
Antibody levels, S/CO			
SARS-COV-2 IgM antibody	0.24 (0.06, 1.19)	0.08 (0.05,0.62)	0.049
SARS-COV-2 IgG antibody	1.57 (0.15, 17.08)	0.12 (0.05,0.31)	<0.001
<b>Treatments</b>			
Corticosteroids	0 (0.00)	1 (2.38)	0.088
Intravenous immunoglobulin	1 (0.23)	1 (2.38)	0.169
Thymosin	52 (11.98)	6 (14.29)	0.850
Arbidol	40 (9.22)	2 (4.76)	0.566
Aerosol interferon-alpha	38 (8.76)	1 (2.38)	0.235

1. Data were expressed as median (interquartile range), or n (%). As appropriate, a comparison between groups was made using Mann-Whitney U-test, Chi-Square test, or Fisher's exact test.

2. COPD, chronic obstructive pulmonary disease; CK-MB, creatine kinase-myocardial band; eGFR, estimated glomerular filtration rate; FDPs, fibrinogen degradation products; Ct, cycle threshold; SARS-COV-2, severe acute respiratory syndrome coronavirus 2.

3. the Ct value from quantitative reverse transcription polymerase chain reaction was used to represent the viral load of SARS-COV-2 in the upper respiratory tract.

**Table 2. Effectiveness of inactivated COVID-19 vaccines against severe illness in patients infected with Delta variant**

	Unvaccinated (Ref.)	Partially vaccinated				Fully vaccinated					
	N	N	OR (95%CI)	P	OR <sub>adj</sub> (95%CI)	P <sub>adj</sub>	N	OR (95%CI)	P	OR <sub>adj</sub> (95%CI)	P <sub>adj</sub>
<b>All patients</b>											
Non-Severe illness	157	92					185				
Severe illness	27	13	0.82 (0.39-1.64)	0.59	1.11 (0.51-2.36)	0.78	2	0.06 (0.01-0.21)	< 0.001	0.11 (0.02-0.45)	0.006
<b>With underlying medical conditions</b>											
Non-Severe illness	68	31					31				
Severe illness	15	4	0.59 (0.16-1.77)	0.374	0.544 (0.14-1.77)	0.34	2	0.29 (0.04-1.12)	0.12	0.26 (0.03-1.23)	0.121
<b>Without underlying medical conditions</b>											
Non-Severe illness	89	60					154				
Severe illness	12	9	1.11 (0.43-2.79)	0.821	1.83 (0.65-5.10)	0.247	0	0	-	0	-
<b>18-59 years</b>											
Non-Severe illness	51	64					171				-
Severe illness	5	5	0.80 (0.21-3.00)	0.731	0.67 (0.17-2.66)	0.562	2	0.12 (0.02-0.57)	0.013	0.12 (0.02-0.61)	0.016
<b>≥60 years</b>											
Non-Severe illness	106	28					14				-
Severe illness	22	8	1.38 (0.53-3.33)	0.491	1.37 (0.52-3.31)	0.502	0	0	-	0	-
<b>Male</b>											
Non-Severe illness	57	43					67				
Severe illness	12	6	0.66 (0.22-1.85)	0.446	0.80 (0.24-2.48)	0.702	2	0.14 (0.02-0.55)	0.013	0.19 (0.03-0.86)	0.049
<b>Female</b>											
Non-Severe illness	100	49					118				
Severe illness	15	7	0.95 (0.35-2.42)	0.921	1.37 (0.47-3.74)	0.545	0	0	-	0	-

OR, odds ratio; CI, confidence interval; OR<sub>adj</sub>, adjusted odds ratio